Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

AstraZeneca 'magic' faces rare test after trial failure, share slide

London: AstraZeneca's long-time CEO Pascal Soriot has ​rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK.

AstraZeneca's huge diversity and number of drugs on the market and success in clinical trials in different therapeutic areas set it apart from peers, giving Soriot the golden touch in the eyes of ‌investors.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.